Abiopharma

Akero Therapeutics (AKRO) Announces Clinical Trial Update Akero Therapeutics (AKRO) provided an update on its clinical development programs. Clinical Development Highlights:

• Clinical Stage: Phase 3, clinical trial
• Collaboration: EFX
  • expected Initiated Jul’21 in 3Q’22 Duration 16 Weeks 16 Weeks 24 Weeks 36 Weeks EFX Doses 28, 50, 70mg 50mg 28, 50mg 28, 50mg Placebo-Controlled üüüü ©2022
  • anticipated in the forward-looking statements, even if new information becomes available in the future. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in our other subsequent filings with the Securities and Exchange Commission. All information in this presentation is as of the date hereof, and we undertake no duty to update this information unless required by law. Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company’s own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. ©2022